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Oral agent offers relief  
from generalized hyperhidrosis 
An inexpensive and well-tolerated anticholinergic 
reduces sweating in those with localized—and 
generalized—hyperhidrosis.
PRACTICE CHANGER
Use low-dose oxybutynin as a first-line treat-
ment option for patients with primary hyper-
hidrosis to improve symptoms and quality 
of life.1
STRENGTH OF RECOMMENDATION 
B: Based on a single, good quality, random-
ized controlled trial. 
Schollhammer M, Brenaut E, Menard-Andivot N, et al. Oxybutynin 
as a treatment for generalized hyperhidrosis: a randomized, placebo-
controlled trial. Br J Dermatol. 2015;173:1163-1168.
ILLUSTRATIVE CASE
A 34-year-old woman presents to your office 
for unbearable sweating. She notes that the 
sweating occurs nearly daily on her hands, 
face, and in her axillary regions, causing social 
embarrassment. She has tried multiple anti-
perspirants to no avail. Is there anything she 
can take to reduce the sweating? 
Hyperhidrosis is a common, self- limiting problem affecting 2% to 3% of the population in the United 
States.2 Patients may complain of localized 
sweating of the hands, feet, face, or under-
arms or more systemic, generalized sweating 
in multiple locations. Either way, patients al-
ways note a significant impact on their qual-
ity of life. 
Treatment of hyperhidrosis has tradi-
tionally focused on topical therapies to the 
affected areas. Research has shown that lo-
calized treatment with antiperspirants con-
taining aluminum salt is effective by both 
subjective report and objective measure-
ments at reducing sweating—particularly 
in the axilla, hands, and feet.3,4 Additionally, 
a systematic review of observational and 
experimental studies found topical glyco-
pyrrolate to be efficacious for craniofacial 
hyperhidrosis with minimal adverse effects.5 
The availability of low-cost prescription and 
over-the-counter aluminum-based antiper-
spirant agents makes topicals the first-line 
choice. 
❚ More invasive treatments are avail-
able for hyperhidrosis that is refractory to 
topicals. In a double-blind, randomized con-
trolled trial, researchers injected either botu-
linum toxin type A (BTX-A) 50 U or placebo 
in patients with bilateral primary axillary hy-
perhidrosis.6 Of the 207 patients who received 
treatment injections, 96.1% had at least a 50% 
reduction of axillary sweating at 4 weeks af-
ter one injection, as measured by gravimetric 
assessment. The BTX-A injections also pro-
duced a prolonged effect; mean duration be-
tween injections was 30.6 weeks.
Other invasive treatments include ionto-
phoresis, surgery, and laser therapy; however, 
these methods are not suitable for body-wide 
application and are, thus, not appropriate for 
patients with generalized hyperhidrosis.
❚ Oxybutynin is the first oral agent to 
emerge as a treatment option for hyperhidro-
sis. This cholinergic antagonist had histori-
cally been used to treat overactive bladder. 
As a cholinergic antagonist, oxybutynin not 
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only reduces urinary frequency, but also 
decreases secretions in various locations 
and, thus, can cause dry mouth and reduce 
perspiration. 
In one prospective placebo-controlled 
trial, 50 patients with generalized hyperhi-
drosis were randomized to receive either 
oxybutynin titrated from 2.5 mg orally once 
daily to 5 mg orally twice daily or placebo 
for 6 weeks.7 Seventeen (73.9%) patients re-
ceiving oxybutynin for palmar or axillary 
hyperhidrosis reported moderate to “great” 
resolution of their symptoms compared with 
6 (27.3%) patients in the placebo group. Dry 
mouth was reported in 34.8% of patients 
receiving oxybutynin vs 9.1% of those who 
received placebo (P=.038); however, no pa-
tients dropped out of the study due to this 
adverse effect.7 
STUDY SUMMARY
This multicenter, randomized controlled trial 
compared oxybutynin to placebo in 62 adults 
with localized or generalized hyperhidrosis 
from 12 outpatient dermatology practices in 
France. It is the first study to include patients 
with a localized, as well as a generalized form 
of the condition. 
Patients were included if they were 
>18 years of age, enrolled in the National 
Health Insurance system in France, and 
reported a Hyperhidrosis Disease Sever-
ity Scale (HDSS) score ≥2. The HDSS is a 
validated, one-question tool (“How would 
you rate the severity of your sweating?”). 
Patients provide a score of 1 (no percep-
tible sweating and no interference with ev-
eryday life) to 4 (intolerable sweating with 
constant interference with everyday life).8 
Patients were excluded if they had any con-
traindications to the use of an anticholinergic 
medication. 
Patients randomized to oxybutynin took 
2.5 mg/d orally initially and increased gradu-
ally over 8 days until reaching an effective 
dose that was not more than 7.5 mg/d. They 
then continued at that dose for 6 weeks. The 
primary outcome was improvement on the 
HDSS by one or more points measured at 
the beginning of the trial and at 6 weeks. Sec-
ondary outcomes included change in quality 
of life, as measured by the Dermatology Life 
Quality Index (DLQI) and reported adverse 
effects. The DLQI is a dermatology-specific 
quality-of-life measure consisting of 10 ques-
tions. Scores range from 0 (where their dis-
ease has no impact on their quality of life) to 
30 (maximum impact of their disease on their 
quality of life).9 
❚ Improved HDSS and DLQI scores. 
Most patients (83%) in the study had gener-
alized hyperhidrosis. Patients were in their 
mid-thirties. Sixty percent of the patients in 
the oxybutynin group had an improvement of 
one point or more on the 4-point HDSS com-
pared to 27% in the placebo group (P<.01). 
DLQI scores improved by 6.9 points in the 
oxybutynin group and 2.3 points in the pla-
cebo group (P<.01). 
❚ The most common adverse effect was 
dry mouth, which occurred in 13 patients 
(43%) in the oxybutynin group and in 3 pa-
tients (11%) in the placebo group (P<.01); it 
did not cause any patients to drop out of the 
study. The second most common adverse ef-
fect was blurred vision, which only occurred 
in the oxybutynin group (4 patients; 13%).
WHAT’S NEW
This is the first randomized controlled trial 
to demonstrate the efficacy of an oral agent 
for generalized primary hyperhidrosis. This 
trial used a relatively low dose of oxybutynin, 
which produced significant benefit while 
minimizing anticholinergic adverse effects. 
CAVEATS
There are many situations for which anti-
cholinergic medications are inappropriate, 
including use by geriatric patients and those 
with gastrointestinal disorders, urinary reten-
tion, or glaucoma. 
CHALLENGES TO IMPLEMENTATION
Few if any challenges exist to the utilization of 
oxybutynin; inexpensive generic versions are 
widely available.                   JFP
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